Osteoblastic metastases in non-small cell lung cancer and its possible significance

Lung Cancer

Volumn 60, Issue 1, 2008, Pages 146-147

  Garfield, David ^a   Cadranel, Jacques ^b   Normanno, Nicola ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b SORBONNE UNIVERSITÉ   (France)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Beta catenin; Bronchioloalveolar carcinoma; EGFR; EGFR mutations; Gefitinib; Non small cell lung cancer; Osteoblastic metastases; Osteomimicry; RANKL; Wnt pathway

Indexed keywords

CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; WNT PROTEIN;

BONE METASTASIS; CANCER GROWTH; CANCER SURVIVAL; DISEASE COURSE; GENE MUTATION; HUMAN; LETTER; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME;

BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; OSTEOBLASTS;

EID: 41149168020     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.01.006     Document Type: Letter

References (13)

1. Tsuya A., Kurata T., Tamura K., and Fukuoka M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 57 (2007) 229-232
2. Langer C.J. Role of zoledronic acid in the setting of bone metastases from non-small-cell lung cancer. Clin Lung Cancer 6 (2005) 314-316
3. Napoli L.D., Hansen H.H., Muggia F.M., and Twigg H.L. The incidence of osseous involvement in lung, with special reference to the development of osteoblastic changes. Radiology 108 (1973) 17-21
4. Garfield D. Increasing osteoblastic lesions as a manifestation of a major response to gefitinib. J Thorac Oncol 1 (2006) 859-860
5. Garfield D.H., Zampa G., Cadranel J., Bell D., Moscato M., and Normanno N. Effects of gefitinib (G) on bone metastases (BMs) in non-small cell lung cancer (NSCLC). ASCO Abstr Part I 24 (2006) 17147 (No. 18S)
6. Berkman Y.M. The many faces of bronchiolo-alveolar carcinoma. Semin Roentgenol 12 (1977) 207-214
7. Talwalkar N.C., Desal A.P., Chawla K.P., Mehta P.J., Gandhi A.K., and Acharya V.N. Alveolar cell carcinoma of the lung with osteoblastic metastases to the spine. J Postgrad Med 26 (1980) 192-195
8. Hill C.A. Bronchioloalveolar carcinoma: a review. Radiology 150 (1984) 15-20
9. Suzuki M., Shigematsu H., Nakajima T., Kubo R., Motohashi S., Sekine Y., et al. Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non-small cell lung cancer. Clin Cancer Res 13 (2007) 6087-6092
10. Boyle W.J., and Simonet W.S. Lacey DL: osteoclast differentiation and activation. Nature 423 (2003) 337-342
11. Normanno N., De Luca A., Aldinucci D., Maiello M.R., Mancino M., D'Antonio A., et al. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastases. Endocr Relat Cancer 12 (2005) 471-482
12. Hall C.L., Kang S., MacDougald O.A., and Keller E.T. Role of Wnts in prostate cancer bone metastases. J Cell Biochem 97 (2006) 661-672
13. Tennis M., Van Scoyk M., and Winn R.A. Role of the Wnt signaling pathway and lung cancer. J Thorac Oncol 2 (2007) 889-892